MXPA03006217A - Sistema de administracion espaciada de farmacos. - Google Patents
Sistema de administracion espaciada de farmacos.Info
- Publication number
- MXPA03006217A MXPA03006217A MXPA03006217A MXPA03006217A MXPA03006217A MX PA03006217 A MXPA03006217 A MX PA03006217A MX PA03006217 A MXPA03006217 A MX PA03006217A MX PA03006217 A MXPA03006217 A MX PA03006217A MX PA03006217 A MXPA03006217 A MX PA03006217A
- Authority
- MX
- Mexico
- Prior art keywords
- drug delivery
- delivery system
- spaced drug
- present
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Abstract
La presente invencion proporciona un metodo para la administracion de dos o mas agentes terapeuticamente activos, que comprende la administracion por via oral a un paciente de un sistema de administracion espaciada de farmacos, donde el momento de la liberacion de los dos o mas agentes terapeuticamente activos esta disenado para proporcionar el control deseado sobre la condicion patologica. La presente invencion tambien proporciona un metodo para la administracion de dos o mas agentes terapeuticamente activos que comprenden la administracion por via oral a un paciente de un sistema de administracion espaciada de farmacos en un momento determinado antes de la ingesta de alimentos por el paciente. La presente invencion tambien proporciona un sistema de administracion espaciada de farmacos que libera dos o mas agentes antidiabeticos terapeuticamente activos en distintos momentos, tras la administraci6n por via oral, para el tratamiento de diabetes mellitus o condiciones asociadas con la diabetes mellitus. Mas particularmente, la presente invencion proporciona un sistema de administracion espaciada de farmacos que libera de inmediato uno o mas agentes antidiabeticos tras la administracion por via oral del sistema, y libera en un pulso uno o mas agentes antidiabeticos en forma confiable, aproximadamente en el momento predeterminado, tras la administracion oral del sistema.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN37MU2001 IN191539B (es) | 2001-01-12 | 2001-01-12 | |
IN324MU2001 | 2001-04-10 | ||
IN326MU2001 | 2001-04-10 | ||
IN323MU2001 | 2001-04-10 | ||
IN325MU2001 | 2001-04-10 | ||
PCT/IN2002/000005 WO2002055009A1 (en) | 2001-01-12 | 2002-01-11 | Spaced drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03006217A true MXPA03006217A (es) | 2004-10-15 |
Family
ID=27517736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03006217A MXPA03006217A (es) | 2001-01-12 | 2002-01-11 | Sistema de administracion espaciada de farmacos. |
Country Status (9)
Country | Link |
---|---|
US (2) | US7964216B2 (es) |
EP (2) | EP1738751B1 (es) |
JP (1) | JP4633329B2 (es) |
AT (1) | ATE508738T1 (es) |
BR (1) | BRPI0206432A2 (es) |
CA (2) | CA2725833A1 (es) |
MX (1) | MXPA03006217A (es) |
PL (1) | PL362687A1 (es) |
WO (1) | WO2002055009A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1377276T3 (da) * | 2001-04-10 | 2012-01-02 | Sun Pharma Advanced Res Co Ltd | Beregning af puls-frigivelsessammensætning |
ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
AU2003281181A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
KR101114808B1 (ko) | 2003-01-29 | 2012-02-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 피복 제제의 제조법 |
US20060210633A1 (en) * | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
US7700128B2 (en) | 2003-10-31 | 2010-04-20 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
US8187633B2 (en) * | 2005-11-03 | 2012-05-29 | Sun Pharma Advanced Research Company Limited | Controlled release coated tablets having prolonged gastric retention |
JP2009537478A (ja) * | 2006-05-13 | 2009-10-29 | ノヴォ ノルディスク アクティーゼルスカブ | レパグリニドとメトホルミンを含む錠剤配合物 |
CA2672602C (en) | 2006-12-18 | 2014-05-20 | Electronic Dietary Foods Inc. | Device for delivery of a substance |
CN101674811B (zh) * | 2007-02-09 | 2015-08-19 | 阿尔法制药有限公司 | 含有两种或更多种不同物理形态的活性药物成分的剂型 |
FR2918567B1 (fr) * | 2007-07-11 | 2012-08-03 | Pf Medicament | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine. |
WO2009009132A1 (en) * | 2007-07-12 | 2009-01-15 | Cougar Biotechnology, Inc. | Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer |
JP2010534721A (ja) * | 2007-07-27 | 2010-11-11 | ディポメド,インコーポレイティド | パルス型胃滞留性製剤 |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
KR20140035331A (ko) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
JP6175074B2 (ja) | 2012-01-06 | 2017-08-02 | エルセリクス セラピューティクス インコーポレイテッド | 代謝障害を治療するための組成物および方法 |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
SG11201505240QA (en) * | 2013-01-05 | 2015-08-28 | Elcelyx Therapeutics Inc | Delayed-release composition comprising biguanide |
PT3007695T (pt) | 2013-06-13 | 2024-03-07 | Akebia Therapeutics Inc | Composições e métodos para tratamento de anemia |
CN104621714B (zh) * | 2014-12-04 | 2018-01-05 | 湖北中烟工业有限责任公司 | 一种提高脆性的烟用添加剂滴丸及其制备方法 |
CN110882261A (zh) * | 2019-12-27 | 2020-03-17 | 无锡福祈制药有限公司 | 二甲双胍格列吡嗪制剂 |
CN113143940A (zh) * | 2020-12-30 | 2021-07-23 | 成都恒瑞制药有限公司 | 一种抗糖尿病药物组合物的制备方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3247066A (en) | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
DE2021147A1 (de) * | 1970-04-30 | 1971-11-11 | Christian Brunnengraeber Chem | Kapsel mit einer Fuellung von Pharmazeutika |
DE2347531A1 (de) * | 1973-09-21 | 1975-04-30 | Hoechst Ag | Arzneizubereitungen zur oralen diabetes-behandlung |
US4252786A (en) | 1979-11-16 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Controlled release tablet |
ZA822995B (en) | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
US4681583A (en) | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
JPS60241871A (ja) * | 1984-05-16 | 1985-11-30 | Ajinomoto Co Inc | アスパルテ−ム含有崩壊錠剤の製造法 |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
CH668187A5 (de) * | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | Therapeutisches system mit systemischer wirkung. |
DE3629994A1 (de) | 1986-09-03 | 1988-03-17 | Weissenbacher Ernst Rainer Pro | Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen |
US4874388A (en) * | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US4976967A (en) | 1987-08-03 | 1990-12-11 | Merck & Co., Inc. | Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts |
US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
GB8913889D0 (en) * | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
EP0408496A3 (en) | 1989-07-12 | 1992-07-01 | Ciba-Geigy Ag | Solid dosage form for pharmaceutical substances |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5474784A (en) | 1990-03-02 | 1995-12-12 | British Technology Group Limited | Dispensing device |
US5226902A (en) * | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
AU2867492A (en) * | 1991-10-10 | 1993-05-03 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
NZ245514A (en) | 1991-12-27 | 1994-12-22 | Merck & Co Inc | Controlled release drug delivery device comprising a core and a polymeric coating which is water impermeable but contains apertures to expose the core |
US5209746A (en) | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
ES2159184T3 (es) | 1997-06-13 | 2001-09-16 | Novo Nordisk As | Nueva posologia para la dmni. |
TR199903096T2 (xx) | 1997-06-18 | 2000-08-21 | Smithkline Beecham P.L.C. | Diabetin tiazolidinedion ve s�lfonil�re ile tedavisi. |
CN1230171C (zh) | 1997-06-18 | 2005-12-07 | 史密丝克莱恩比彻姆有限公司 | 用噻唑烷二酮和二甲双胍治疗糖尿病 |
GB9715306D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
GB9715298D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
GB9715295D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
PT1021171E (pt) | 1997-10-09 | 2003-10-31 | Dexcel Pharma Technologies Ltd | Sistema de administracao de farmacos no tracto gastrointestinal de libertacao total prolongada |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
EP1039890B1 (en) | 1997-12-08 | 2004-03-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
AP1224A (en) * | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
DK0974356T3 (da) * | 1998-07-15 | 2003-10-27 | Merck Sante Sas | Tabletter omfattende en kombination af metformin og glibenclamid |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
WO2000025757A1 (en) | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | Sustained release delivery of highly water-soluble compounds |
US6096341A (en) * | 1998-10-30 | 2000-08-01 | Pharma Pass Llc | Delayed release tablet of bupropion hydrochloride |
SI1131070T1 (sl) | 1998-11-12 | 2008-12-31 | Smithkline Beecham Plc | Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina |
DE19860698A1 (de) * | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
AU4221300A (en) * | 1999-04-06 | 2000-10-23 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
JP2003504415A (ja) * | 1999-07-20 | 2003-02-04 | メルク エンド カムパニー インコーポレーテッド | 持続放出性薬物分散剤輸送装置 |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
EP1095650A1 (en) | 1999-10-29 | 2001-05-02 | Universiteit Leiden | Double phase time-controlled release system |
US6352721B1 (en) | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
US6491949B2 (en) | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
AR026148A1 (es) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
US6376682B1 (en) * | 2000-02-01 | 2002-04-23 | Takama System, Ltd. | Compound with α-glucosidase inhibiting action and method for producing the same |
ATE340563T1 (de) * | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
DK1377276T3 (da) | 2001-04-10 | 2012-01-02 | Sun Pharma Advanced Res Co Ltd | Beregning af puls-frigivelsessammensætning |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
US20060210633A1 (en) * | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
-
2002
- 2002-01-11 US US10/466,036 patent/US7964216B2/en not_active Expired - Fee Related
- 2002-01-11 JP JP2002555746A patent/JP4633329B2/ja not_active Expired - Fee Related
- 2002-01-11 MX MXPA03006217A patent/MXPA03006217A/es active IP Right Grant
- 2002-01-11 WO PCT/IN2002/000005 patent/WO2002055009A1/en active Application Filing
- 2002-01-11 PL PL02362687A patent/PL362687A1/xx not_active Application Discontinuation
- 2002-01-11 EP EP06019650A patent/EP1738751B1/en not_active Expired - Lifetime
- 2002-01-11 BR BRPI0206432A patent/BRPI0206432A2/pt not_active IP Right Cessation
- 2002-01-11 EP EP02710296A patent/EP1349531A1/en not_active Withdrawn
- 2002-01-11 CA CA2725833A patent/CA2725833A1/en not_active Abandoned
- 2002-01-11 CA CA2434169A patent/CA2434169C/en not_active Expired - Fee Related
- 2002-01-11 AT AT06019650T patent/ATE508738T1/de not_active IP Right Cessation
-
2011
- 2011-06-17 US US13/163,168 patent/US20110250271A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1738751A3 (en) | 2007-01-17 |
EP1349531A1 (en) | 2003-10-08 |
ATE508738T1 (de) | 2011-05-15 |
CA2434169A1 (en) | 2002-07-18 |
US7964216B2 (en) | 2011-06-21 |
JP4633329B2 (ja) | 2011-02-16 |
BRPI0206432A2 (pt) | 2016-10-25 |
US20110250271A1 (en) | 2011-10-13 |
CA2725833A1 (en) | 2002-07-18 |
US20040086562A1 (en) | 2004-05-06 |
EP1738751B1 (en) | 2011-05-11 |
PL362687A1 (en) | 2004-11-02 |
JP2004523510A (ja) | 2004-08-05 |
CA2434169C (en) | 2011-03-15 |
EP1738751A2 (en) | 2007-01-03 |
WO2002055009A1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03006217A (es) | Sistema de administracion espaciada de farmacos. | |
WO2003077972A8 (en) | Implantable drug delivery system | |
NZ598502A (en) | Use of vegf antagonists in intraocular neovascular disease treatment | |
WO2007098479A3 (en) | Localized insulin delivery for bone healing | |
WO2004071529A3 (en) | Uses of anti-insulin-like growth factor i receptor antibodies | |
RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
BR9906813A (pt) | Método para administração de insulina aspb28- humana | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
MXPA05012810A (es) | Formas de dosis oral de memantina. | |
NO20080244L (no) | Doseringsstyring for prasugrel | |
MXPA02003495A (es) | Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos. | |
JP2004537500A5 (es) | ||
CA2403994A1 (en) | Nasal administration of agents for the treatment of gastroparesis | |
WO2003097050A3 (en) | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases | |
PL1680112T3 (pl) | N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę | |
MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
JP2004503471A5 (es) | ||
RU2002117537A (ru) | Способ лечения последствий тканевой гипоксии у пациентов в критическом состоянии | |
JP2001316293A5 (es) | ||
DE60111919D1 (de) | Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten | |
Fu et al. | A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients | |
WO2002043566A3 (en) | Devices and methods for treating low blood sugar levels | |
WO2001045642A3 (en) | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease | |
MD1780F1 (en) | Method of treatment of patients with hepatic cirrhosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |